Company news

Heron Therapeutics, Inc. news in 2024

Heron Therapeutics, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Heron Therapeutics Announces Corporate Headquarters Relocation to Cary, North Carolina

December 22, 2024

U.S. District Court Upholds Validity of CINVANTI® Patents

December 2, 2024

Heron Therapeutics Announces Third Quarter 2024 Financial Results and Narrows Financial Guidance

November 11, 2024

Heron Therapeutics Announces Appointment of Michael Kaseta to Board of Directors

November 3, 2024

Heron Therapeutics to Report Third Quarter 2024 Financial Results On Tuesday, November 12, 2024

October 28, 2024

Heron Therapeutics Reaffirms Availability and Ample Supply of CINVANTI®, SUSTOL®, and APONVIE® as Alternatives During the Potential Shortage of Intravenous Fluids

October 9, 2024

Heron Therapeutics Announces FDA Approval of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN")

September 24, 2024

Heron Therapeutics Announces Appointment of Brett Fleshman as Chief Business Officer

September 2, 2024

Heron Therapeutics Announces Second Quarter 2024 Financial Results and Narrows Financial Guidance

August 5, 2024

Heron Therapeutics to Report Second Quarter 2024 Financial Results On Tuesday, August 6, 2024

July 29, 2024

Heron Therapeutics Announces the Inclusion of ZYNRELEF® as a Qualifying Product Under the Proposed 2025 Non-Opioid Policy for Pain Relief Under the OPPS and the ASC Payment System

July 14, 2024

Heron Therapeutics Announces Acceptance of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN")

July 1, 2024

Heron Therapeutics Announces Prior Approval Supplement Submission to the FDA for ZYNRELEF® Vial Access Needle ("VAN")

May 28, 2024

Heron Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Corporate Updates

May 6, 2024

Heron Therapeutics to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024

April 23, 2024

Heron Therapeutics to Host Investor Day on May 15, 2024 in New York City

April 10, 2024

Heron Therapeutics Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference

March 27, 2024

Heron Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Updates

March 11, 2024

Heron Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results On Tuesday, March 12, 2024

February 27, 2024

Heron Therapeutics Announces FDA Approval of ZYNRELEF® Indication Expansion to Include Additional Orthopedic and Soft Tissue Procedures

January 22, 2024

Heron Therapeutics Announces Partnership with CrossLink Life Sciences to Expand Promotional Effort for ZYNRELEF®, the First and Only Non-Opioid Dual Acting Local Anesthetic for Post-Operative Pain

January 6, 2024

Calls in 2024